Free tool
FAERS Monitor: Risperdal
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021444 or its brand name (Risperdal, Risperidone). Reports on generic versions are filed under their own applications.
Reports
121,690
Serious
83,506
69% of reports
Hospitalization
38,163
Death reported
9,509
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- gynaecomastia24,513
- off label use12,041
- abnormal weight gain9,418
- weight increased8,955
- drug ineffective7,407
- product use in unapproved indication5,949
- emotional disorder5,930
- injury4,624
- drug interaction4,510
- hyperprolactinaemia4,431
- somnolence4,366
- galactorrhoea3,713
- obesity3,706
- emotional distress3,524
- extrapyramidal disorder3,385
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,082 |
| 2005 | 2,052 |
| 2006 | 2,349 |
| 2007 | 2,212 |
| 2008 | 2,285 |
| 2009 | 3,901 |
| 2010 | 3,696 |
| 2011 | 3,714 |
| 2012 | 3,766 |
| 2013 | 3,060 |
| 2014 | 4,165 |
| 2015 | 12,683 |
| 2016 | 13,514 |
| 2017 | 13,077 |
| 2018 | 6,719 |
| 2019 | 7,609 |
| 2020 | 6,051 |
| 2021 | 4,894 |
| 2022 | 5,336 |
| 2023 | 4,928 |
| 2024 | 5,303 |
| 2025 | 4,852 |
| 2026 | 3,441 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,932,469 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gynaecomastiaSignal | 24,513 | 653.2 | 635.9 | 3,332,238 |
| abnormal weight gainSignal | 9,418 | 549.7 | 527.6 | 1,230,031 |
| hyperprolactinaemiaSignal | 4,431 | 370.4 | 351.6 | 517,700 |
| galactorrhoeaSignal | 3,713 | 235.1 | 223.8 | 365,693 |
| obesitySignal | 3,706 | 52.1 | 50.2 | 142,601 |
| emotional disorderSignal | 5,930 | 40.9 | 39.8 | 186,826 |
| extrapyramidal disorderSignal | 3,385 | 27.1 | 26.2 | 73,614 |
| injurySignal | 4,624 | 12.1 | 11.7 | 44,116 |
| weight increasedSignal | 8,955 | 7.2 | 7.0 | 46,026 |
| emotional distressSignal | 3,524 | 5.2 | 5.0 | 11,510 |
| drug interactionSignal | 4,510 | 5.0 | 4.9 | 14,243 |
| product use in unapproved indicationSignal | 5,949 | 4.2 | 4.1 | 14,467 |
| somnolenceSignal | 4,366 | 3.8 | 3.7 | 8,929 |
| off label useSignal | 12,041 | 2.4 | 2.4 | 10,077 |
| drug ineffective | 7,407 | 1.0 | 0.9 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.